Good news for a troubled Ohio life sciences company? An Akron-based investment group recently acquired Ricerca Biosciences for an undisclosed sum. While in August Ricerca warned the state of Ohio that it might have to lay off its 200 employees, according to Crain’s Cleveland Business, it’s instead found a private buyer – Main Market Partners LLC. Ricerca has been around […]
Faced with a recent slowdown in much of the contract research organization (CRO) industry, Ricerca Biosciences LLC has tweaked its focus to solidify its future. The Concord Township, Ohio-based company has shaken up its client base to include more pharmaceutical firms and is growing its Asian operations to take advantage of the increasingly lucrative market.
Contract drug-development organization Ricerca Biosciences LLC is offering a new service that compares drug candidates to a large reference set of pharmacologically active compounds. The new service, called Foresight, helps predict in vivo effects from in vitro drug data and provides insight into additional compound activities, according to a statement from Concord Township, Ohio-based Ricerca. […]
Contract drug development organization Ricerca Biosciences LLC has completed its acquisition of the discovery and preclinical business of MDS Pharma Services, more than doubling its workforce and multiplying its global capabilities. Ricerca in Concord Township, Ohio, paid $35 million, less normal working capital and a two-year capital expenditure reserve, according to Ian Lennox, Ricerca’s chairman […]
Contract drug development organization Ricerca Biosciences LLC has agreed to acquire the discovery and preclinical business of MDS Pharma Services for $35 million less working capital and cap-ex reserve.
MedWish International still is collecting medical supplies for victims of the Haitian earthquake while Ohio doctors, nurses and other medical professionals volunteer to help.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Two trends helped give Ohio a seat at the bioscience leaders table last year: Big drug companies farmed out more of their research and manufacturing work -- to contract research and manufacturing organizations in the state. And a record number of biomedical companies started up or moved to the state, primarily in Northeast Ohio.
Biomedical companies with compelling technologies could win millions of dollars in investments this year despite the worst gloom in financial markets since the Great Depression.
